Moderna fell in trading on Thursday after its vaccine revenues missed analysts’ expectations and the company made a small increase in product sales projections for the year.

US government support of a waiver of patent protections for Covid-19 vaccines at the World Trade Organization is also weighing on Moderna’s shares...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.